Abstract:Objective This study was performed to assess the potential factors for poor short-term first-line treatment response, the appropriate further treatment options, and the prognosis in patients with autoimmune encephalitis (AE). Methods This retrospective study consisted of 135 patients with AE. According to their short-term first-line treatment response, patients were divided into the response group and the non-response group. The demographics, clinical characteristics, main accessory examinations, immunotherapy, and outcomes of patients were compared between the two groups. Univariate and multivariate logistic regression models were used to analyze whether non-responders have poor long-term outcomes. Further treatment and prognosis of non-responders were also analyzed. Results Of the 128 patients who were treated with first-line immunotherapy, 59 (46.1%) were non-responders. Patients in the non-response group had more symptoms and exhibited a higher proportion of mental behavior disorder, central hypoventilation, and autonomic nervous dysfunction. The modified Rankin scale (mRS) scores and neutrophil-to-lymphocyte ratio (NLR) levels were significantly higher and albumin, high-density lipoprotein cholesterol (HDL-C), apolipoprotein A (apoA) levels were significantly lower in the non-response group ( p < 0.05, all). Multivariate logistic regression analysis showed that the number of clinical symptoms, mental behavior disorder, central hypoventilation, maximum mRS score, and albumin level was independently associated with non-response to short-term first-line treatment. Non-responders had poor long-term outcomes compared with the responders at all times of followed-up ( p < 0.05, all). In multivariable analysis, initial first-line treatment response was independently associated with the long-term prognosis, both at 12-month [odds ratio (OR), 4.74, 95% CI, 1.44–15.59, and p =0.010] and 24-month follow-ups (OR, 8.81, 95% CI, 1.65–47.16; and p = 0.011). Among the non-responders, a higher improvement of mRS scores was observed in those who received second-line treatment than those who had no further treatment or repetition of first-line immunotherapy in the follow-up. However, the rate of a good outcome and median mRS scores were not significantly different among the three groups. Conclusion Disease severity, clinical features, anti-N-methyl-D-aspartate receptor subtypes, antibody titers, NLR, albumin, HDL-C, and apoA levels were all associated with non-response to short-term first-line treatment. The short-term first-line treatment response is a valuable predictor of long-term outcomes in patients with AE. Second-line immunotherapy may be a more aggressive treatment option for patients who failed short-term first-line immunotherapy.

An Update on the Treatment of Pediatric Autoimmune Encephalitis

Treatment Approaches in Pediatric Relapsing Autoimmune Encephalitis

Prognostic factors and treatment outcomes in pediatric autoimmune encephalitis: a multicenter study

Treatment strategies for autoimmune encephalitis

Immunotherapy for Refractory Autoimmune Encephalitis

Treatment Options in Refractory Autoimmune Encephalitis

Autoimmune encephalitis and immune therapy: lessons from Argentina

Suspected autoimmune encephalitis: A retrospective study of patients referred for therapeutic plasma exchange

Immune therapy in autoimmune encephalitis: a systematic review

Navigating the diagnostic and therapeutic complexities of autoimmune encephalitis

First-line Immunotherapy of Neuronal Surface Antibody-Mediated Autoimmune Encephalitis: Assessment of Therapeutic Effectiveness and Cost-Efficiency

Autoimmune Encephalitis: Insights Into Immune-Mediated Central Nervous System Injury

Efficacy and safety of rituximab in autoimmune encephalitis: A meta‐analysis

Autoimmune encephalitis: proposed recommendations for symptomatic and long-term management

Immunotherapy in Probable autoimmune encephalitis without detected autoantibody

Immunotherapy in Autoantibody-Associated Psychiatric Syndromes in Adults

Autoimmune Encephalitis in Children: A Case Series at a Tertiary Care Center

Immunotherapy and prognosis of autoimmune encephalitis

B-cell targeted therapies in autoimmune encephalitis: mechanisms, clinical applications, and therapeutic potential

Influential Factors, Treatment and Prognosis of Autoimmune Encephalitis Patients With Poor Response to Short-Term First-Line Treatment

Rituximab Treatment and Long-term Outcome of Patients With Autoimmune Encephalitis